Antibiotic Resistance Market Analysis

Antibiotic Resistance Disease Market Analysis

To get key market trends

  Download Free Sample

Based on disease, the antibiotic resistance market is categorized into complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), bloodstream infection (BSI), acute bacterial skin and skin-structure infection (ABSSSI), community-acquired bacterial pneumonia (CABP), clostridium difficile infections (CDI), and hospital-acquired bacterial pneumonia (HABP). In 2022, the complicated urinary tract infections segment held the highest market share of 24.7%. The factors contributing to the growth are increasing incidence of cUTI, strong product pipeline, and increasing prevalence of underlying medical conditions like diabetes and kidney diseases which are more likely to develop cUTI. Due to the severity and complication of cUTIs, such patients require the use antibiotics with broader spectrum coverage to target a wider range of potential pathogens, including drug-resistant strains.
 

Based on pathogen, the antibiotic resistance market is segmented into E. coli, K. pneumoniae, P. aeruginosa, S. aureus, Baumannii, S. pneumoniae, H. influenzae, C. difficile, and E. faecium. Among the pathogens, the E. coli segment accounted for highest market share and was valued at USD 2.2 billion in 2022. K. pneumoniae held the second highest market share of 21.4%. This is due to the high incidence rate antibiotic resistant infections caused by Enterobacteriaceae which includes E. coli and K. pneumoniae. According to the National Institutes of Health, it is estimated that each year 140,000 health care associated Enterobacteriaceae infections occur in the U.S. During the forecast period, C. difficile is expected to grow at fastest CAGR followed by P. aeruginosa strains which is responsible for high morbidity and mortality rate leading to prolonged treatment and higher costs treatment cost compared to other infections.
 

Based on drug class, the antibiotic resistance market is classified into oxazolidinones, cephalosporin, lipoglycopeptides, combination therapies, tetracyclines, and other drug classes. The oxazolidinones segment held largest business share of 14% and is expected to grow at CAGR of 5.1% over the coming years. Oxazolidinones, especially Linezolid, which has strong activity against both aerobic and anaerobic of Gram-positive bacteria, including those that are resistant to multiple other classes of antibiotics. They are bacteriostatic antibiotics, that means they inhibit bacterial growth and does not kill the bacteria directly. The bacterial proliferation can be prevented by using such mode of action. During the forecast period, combination therapies segment is anticipated to witness growth at CAGR of 8% due to the growing burden of antibiotic-resistant Gram-negative infections.
 

Based on the mechanism of action, the antibiotic resistance market is segmented into cell wall synthesis inhibitors, protein synthesis inhibitors, DNA synthesis inhibitors, RNA synthesis inhibitors, and other mechanism of actions. The cell wall synthesis inhibitors segment held highest market share and was valued to be USD 2.6 billion in 2022. They have broad spectrum activity against a broad range of bacteria, such as Gram-positive and some Gram-negative species which results in widespread use and higher prescription rates. The RNA synthesis inhibitors are expected to grow at fastest CAGR during the forecast period due to the unique mode of action by disrupting the transcription process and broad-spectrum activity.

Based on the distribution channel, the antibiotic resistance market is segmented into hospital, retail, and online pharmacies. In 2022, the hospital pharmacies segment accounted for highest revenue share of 54%. Hospital pharmacies often participate in antimicrobial stewardship programs ensuring that antibiotics are prescribed properly as per the clinical need, susceptibility data, and guidelines. The hospital pharmacies provide optimum dosing ensuring that antibiotics are dosed correctly based on patient condition. The online pharmacies segment is projected to grow at fastest CAGR during the forecast period as it offers convenience and accessibility. Some online pharmacies need valid prescription to order such antibiotics which is significantly reducing the overuse and misuse of antibiotics.
 

In 2022, the North American antibiotic resistance market is expected to reach USD 5.5 billion by 2032. The region has a relatively high prevalence of antibiotic resistant infections as the region has one of the highest rates of antibiotic consumption. Moreover, the increasing research and development activities related to antibiotics, increasing government support and fundings, and presence of key players operating in this market are expected to drive the growth of this market.